Epidemiological profile and clinical characteristics of patients with intestinal inflammatory disease

Journal of Coloproctology - Tập 37 - Trang 273-278 - 2017
Jhelly Aparecida Valcanaia Arantes1,2, Carlos Henrique Marques dos Santos3, Breno Matos Delfino2,4, Bruno Alexandre da Silva5, Rafaela Maria Maran de Souza1, Thaynara Maria Maran de Souza1, Isabella Demeis Flávio6, Caroline Gil Ferreira1, Samuel Bellin Gomes da Cruz1
1Universidade Anhanguera Uniderp, Campo Grande, MS, Brazil
2Hospital Regional de Mato Grosso do Sul, Campo Grande, MS, Brazil
3Sociedade Brasileira de Coloproctologia, Campo Grande, MS, Brazil
4Universidade Federal do Acre (UFAC), Rio Branco, AC, Brazil
5Universidade de Aquino (UDABOL), Santa Cruz de la Sierra, Bolivia
6Universidade Anhanguera (UNIDERP), Campo Grande, MS, Brazil

Tóm tắt

AbstractAccording to several epidemiological studies, there is a significant increase in cases of inflammatory disease in developing countries. Objective To describe epidemiological data and clinical features of patients with inflammatory bowel disease in patients enrolled in Campo Grande, MS. Method A retrospective descriptive study with a database analysis of patients who were enrolled and renewed their process in the Exceptional Medications Program of the Health Department from January 2008 to December 2016. Results 423 patients participated in the study, 260 women and 163 men. Of these, 238 patients had Crohn's disease and 185 had ulcerative rectocolitis. The patients’ mean age was 46 years. The most commonly used medication for both diseases was mesalazine and 34.3% of the patients needed to switch their medication during the treatment, most of them with Crohn's disease. In Crohn's patients, the most affected segment was the colon (40.6%) and in patients with ulcerative rectocolitis the entire large intestine was involved (78.8%) was more common. Of the total number of patients, 10.8% of the women and 18.4% of the men needed to use an anti-TNF. Conclusion Most people on treatment for IBD are female, with a mean age of 46 years and suffering from Crohn's disease. The most affected segments were the entire large intestine in URC cases and the colon in Crohn's disease cases. Mesalazine was the most used drug in both diseases. There was more drug replacement in Crohn's disease patients. In Crohn's disease, younger patients used infliximab more frequently.

Tài liệu tham khảo

World Gastroenterology Organisation Practice Guidelines. Doença Inflamatória Intestinal: uma perspectiva global – 2009. Available from: http://www.worldgastroenterology.org/UserFiles/file/guidelines/inflammatory-bowel-disease-portuguese-2009.pdf Oliveira, 2010, Aspectos epidemiológicos das doenças intestinais inflamatórias na macrorregião de saúde leste do estado de minas gerais, Ciênc Saúde Coletiv, 15, 1031, 10.1590/S1413-81232010000700009 Maranhão, 2015, Características e diagnóstico diferencial das doenças inflamatórias intestinais, J Bras Med, 103, 9 Souza, 2008, The epidemiological profile of patients with inflammatory bowel disease in the State of Mato Grosso, Rev Bras Coloproct, 28, 324, 10.1590/S0101-98802008000300009 2008, Projeto diretrizes Cabral, 2012, Diganóstico das doenças inflamatórias intestinais, Rev Hosp Univ Pedro Ernesto, 11, 17 2009, Consensus guidelines for the management of Crohn's disease in adults, Am J Gastroenterol Adv Online 2010, Consensus guidelines for the management of inflammatory bowel disease, Arq Gastroenterol, 47, 313, 10.1590/S0004-28032010000300019 Kleinubing-Júnior, 2011, Perfil dos pacientes ambulatoriais com doenças inflamatórias intestinais, ABCD: Arq Bras Cir Dig, 24, 200 2008, Projeto diretrizes Strong, 2015, Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. Clinical Practice Guidelines for the Surgical Management of Crohn's Disease, Dis Colon Rectum, 58, 1021, 10.1097/DCR.0000000000000450 Habr-Gama, 2011, Doença de Crohn intestinal: manejo, Rev Assoc Med Bras, 57, 10, 10.1590/S0104-42302011000100006 Van den Brande, 2003, Infliximab but not Etanerecept induces apoptosis in lamina propria Tlymphocytes from patients with Crohn's disease, Gastroenterology, 124, 1774, 10.1016/S0016-5085(03)00382-2 Terdiman, 2013, American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease, Gastroenterology, 145, 1459, 10.1053/j.gastro.2013.10.047 Kotze, 2010, Reindução da remissão clínica com adalimumabe após interrupção do tratamento: uma alternativa no manejo da doença de Crohn, Rev Bras Coloproctol, 30, 135, 10.1590/S0101-98802010000200003 Targan, 1997, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis-factor á for Crohn's disease, N Engl J Med, 337, 1029, 10.1056/NEJM199710093371502 Rutgeerts, 2006, Review article: infliximab therapy for inflammatory bowel disease – seven years on, Aliment Pharmacol Ther, 23, 451, 10.1111/j.1365-2036.2006.02786.x
Thông tin
Thông tin xuất bản

Journal of Coloproctology

Tập 37

273-278

Thông tin tác giả